Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Adjuvant therapy for DTC
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== '''Approach:''' == * Risk stratify the patient ** Imaging findings ** Operative findings ** Histopathology ** Molecular testing if available * Give levothyroxine to suppress TSH * Give RAI if indicated * Consider EBRT * Dynamic risk stratification: reclassify and alter treatment accordingly as more information becomes available throughout follow-up == '''ATA risk stratification system to estimate risk of persistent/recurrent disease''' == {| class="wikitable" | {| class="wikitable" |'''Low risk''' |- |'''Papillary thyroid cancer with all of the following present:''' |- | ** No local or distant metastases |- | ** All macroscopic tumor has been resected |- | ** No invasion of locoregional tissues |- | ** Tumor does not have aggressive histology (aggressive histologies include tall cell, insular, columnar cell carcinoma, Hürthle cell carcinoma, follicular thyroid cancer, hobnail variant) |- | ** No vascular invasion |- | ** No 131I uptake outside the thyroid bed on the post-treatment scan, if done |- | ** Clinical N0 or ≤5 pathologic N1 micrometastases (<0.2 cm in largest dimension)* |- |'''Intrathyroidal, encapsulated follicular variant of papillary thyroid cancer*''' |- |'''Intrathyroidal, well-differentiated follicular thyroid cancer with capsular invasion and no or minimal (<4 foci) vascular invasion*''' |- |'''Intrathyroidal, papillary microcarcinoma, unifocal or multifocal, including ''BRAF'' V600E mutated (if known)*''' |} | {| class="wikitable" |'''Intermediate risk''' |- |'''Any of the following present:''' |- |Microscopic invasion into the perithyroidal soft tissues |- |Cervical lymph node metastases or 131I avid metastatic foci in the neck on the post-treatment scan done after thyroid remnant ablation |- |Tumor with aggressive histology or vascular invasion (aggressive histologies include tall cell, insular, columnar cell carcinoma, Hürthle cell carcinoma, follicular thyroid cancer, hobnail variant) |- |Clinical N1 or >5 pathologic N1 with all involved lymph nodes <3 cm in largest dimension* |- |Multifocal papillary thyroid microcarcinoma with extrathyroidal extension and ''BRAF'' V600E mutated (if known)* |} | {| class="wikitable" |'''High risk''' |- |'''Any of the following present:''' |- |Macroscopic tumor invasion |- |Incomplete tumor resection with gross residual disease |- |Distant metastases |- |Postoperative serum thyroglobulin suggestive of distant metastases |- |Pathologic N1 with any metastatic lymph node ≥3 cm in largest dimension* |- |Follicular thyroid cancer with extensive vascular invasion (>4 foci of vascular invasion)* |} |} == '''TSH suppression''' == * Rationale: prevent TSH stimulating ectopic thyroid tissue, with lifelong levothyroxine. Improves overall survival, but no clear best degree of suppression. * Low-risk: ** Detectable Tg: TSH 0.1 - 0.5 mU/L ** Undetectable Tg: TSH 0.5 to 2 mU/L * Intermediate: TSH 0.1 - 0.5 mU/L * High: TSH < 0.1 mU/L * Long-term, have to balance benefits of TSH suppression with clinical risks of hyperthyroidism, such as osteoporosis and AF * If patients have excellent response to therapy, consider relaxing target == '''Radioiodine ablation''' == * Tumour type and operation ** Useful with PTC and FTC ** Commonly given with HCC too, although not as effective ** Not given for PDTC, MTC and ATC ** Obviously contraindicated if only hemithyroidectomy was performed * Risk profile ** Low-risk: not routinely given ** Intermediate risk: selective but usually give at lower dose like 30mCi (microscopic or vascular invasion, significant lymph node metastases, aggressive histology) ** High-risk: give, usually at a higher dose like 100mCi * Indications ** Ablate residual normal thyroid tissue (increase specificity of serum Tg for surveillance; prevent subsequent de novo cancer; treat microscopic disease) ** Treat clinically detectable disease not addressed by surgery * Protocol ** Should be administered in a low-iodine state and high TSH levels, to maximise RAI uptake by thyroid tissue ** Patient needs to be in isolation for 24-48 hours ** Improves disease-free survival via ablation of residual or metastatic disease ** Remnant ablation dose - 30-50mCi ** Treatment dose - 100-150mCi ** Pregnancy and breastfeeding are absolute contraindications; don't become pregnant for six months afterwards ** Risks - sialadenitis, nasolacrimal duct obstruction, transient tumour/thyroid swelling, infertility, development of secondary malignancies (leukaemia) == Also consider adjuvant '''external beam radiation therapy''' == * Local control of unresectable locally advanced macroscopic or microscopic residual disease after thyroidectomy (especially RAI non-avid) * Treatment of symptomatic distant metastatic foci that are RAI non-avid [[Category:Endocrine]]
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Adjuvant therapy for DTC
Add topic